TABLE 3.

Incidence Rates of Non-histological Outcomes Among 114 HBV-HIV Co-infected North American Adults With > 24 Weeks of Follow-up

	No. of Participants With the Outcome (Person-Years¶)	Incidence per 100 Person-Years (95% CI)
Primary clinical outcomes (n = 114*)
Hepatic decompensation	1 (329.5)	0.30 (0.04, 2.15)
HCC	2 (326.1)	0.61 (0.15, 2.45)
Liver transplant†	0 (331.3)	—
HBV-related death†	1 (332.1)	0.30 (0.04, 2.14)
Composite clinical outcome‡	2 (326.1)	0.61 (0.15, 2.45)
Secondary outcomes (n indicated below)
Incident cirrhosis (n = 104 without baseline cirrhosis)	1 (248.5)	0.40 (0.06, 2.86)
Incident ALT flare (n = 111 with follow-up ALT)	2 (305.5)	0.65 (0.16, 2.62)
Ever become HBsAg-negative (n = 104 HBsAg-positive with follow-up HBsAg)	0 (296.2)	NA
Ever become HBeAg-negative (n = 67 HBeAg-positive with follow-up HBeAg)	13 (189.5)	6.86 (3.98, 11.81)
Non-HBV-related death (n = 114)§	4 (333.0)	1.20 (0.45, 3.20)

^*Includes those with baseline cirrhosis (developed before or within 24 weeks after enrollment).

^†No transplants or deaths occurred within 24 weeks of study entry.

^‡Defined as first of decompensation, HCC, liver transplant, or HBV-related death.

^§The 4 participants with non-HBV deaths did not have any of the other outcomes presented in this table

^¶Time to event or end of follow-up.

Abbreviation: NA, not available.